动物造模,前列腺癌人源性异种移植裸鼠模型 z-bio 2022-02-01 687

　　Objective: To establish a human-derived xenograft (PDX) model of prostate cancer and evaluate the anti-tumor efficacy of various treatment options?

　　Methods: Fresh human prostate cancer surgical specimens were mixed with Matrigel and source androgen, and the tumor growth was monitored subcutaneously and the fidelity continuous passage was assessed; the cancer-bearing mice were divided into four groups: docetaxel group, castrated group, and dose paclitaxel In the combined sterilization group and the control group, the tumor volume and changes during treatment were weighed. After treatment, the total prostate specific antigen (tPSA) level and serum histopathological changes to assess the efficacy?

　　Results: The PDX model successfully established pathological analysis of prostate cancer, including hormone-sensitive tumors (D17225) and castration resistant (C40019) tumors, indicating that transplanted tumors better maintain the key characteristics of the patient's primary tumor. It turns out. In the D17225 model, does the combined castration group show a good therapeutic effect, while the latter shows a more obvious tumor suppressor effect?

　　Conclusion: The PDX model of prostate cancer was successfully established and passaged stably. Hormone sensitivity (D17225) has a significant therapeutic effect on the PDX model of prostate cancer?